Summary of Key Points Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance fund efficiency while ensuring the safety of the funds and not affecting ongoing projects or daily operations [1][10]. Group 1: Fundraising and Management - The company raised a total of RMB 1,145.54 million through the issuance of 38,428,000 shares at a price of RMB 29.81 per share, with a net amount of RMB 1,067.13 million after deducting issuance costs [1][3]. - As of June 30, 2025, the total amount invested in fundraising projects was RMB 504.97 million, with RMB 570 million allocated for cash management, leaving a balance of RMB 53.82 million in the fundraising account [2][3]. Group 2: Cash Management Plan - The company aims to use up to RMB 700 million of idle funds for cash management, with a rolling usage period of 12 months from the board's approval date [5][10]. - The investment products will include low-risk, high-liquidity options such as structured deposits, time deposits, and large certificates of deposit, ensuring that these funds are not used for pledging or securities investment [5][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not impact the normal operation of fundraising projects or the company's production activities [10][11]. - The sponsor, Huatai United Securities, has conducted a review and found that the cash management plan complies with relevant regulations and does not harm the interests of shareholders, particularly minority shareholders [11].
春立医疗: 华泰联合证券有限责任公司关于北京市春立正达医疗器械股份有限公司使用部分闲置募集资金进行现金管理的核查意见